Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16:10 | After Amgen's stumble, BMS touts KRAS confirmatory trial win for newly bought Krazati | 2 | FiercePharma | ||
16:01 | NovaBay Pharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
15:31 | Bayer mit EILMELDUNG: Experte setzt WAHNSINNS Kursziel - Dringend vor dem Wochenende handeln! | Hebelschein-Spekulant | |||
15:10 | Old tweet, new problem: PMCPA chides Pfizer over UK staffer's 2020 Twitter misstep | 4 | FiercePharma | ||
14:50 | Bristol Myers Squibb Company: Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes | 208 | ACCESSWIRE | Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United KingdomOriginally published on Bristol Myers Squibb NewsroomPRINCETON, NJ / ACCESSWIRE / March 29, 2024... ► Artikel lesen | |
14:46 | SCYNEXIS Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
14:46 | Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
14:22 | Molecular Templates Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
14:22 | KALA BIO Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
14:18 | Willow Biosciences GAAP EPS of -C$0.10, revenue of C$1.17M | 1 | Seeking Alpha | ||
14:10 | Bristol Myers Squibb's versatile Zeposia doesn't make the grade in Crohn's disease trial | 4 | FiercePharma | ||
14:10 | Galectin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
14:05 | Trulieve Cannabis Corp. - 8-K, Current Report | 1 | SEC Filings | ||
14:01 | Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals | 1 | The Motley Fool | ||
13:58 | Molecular Templates, Inc. - 10-K, Annual Report | - | SEC Filings | ||
13:42 | Molecular Templates GAAP EPS of -$0.73, revenue of $7.02M | 1 | Seeking Alpha | ||
13:42 | Galectin Therapeutics GAAP EPS of -$0.74 | 1 | Seeking Alpha | ||
13:42 | Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44 | 1 | Seeking Alpha | ||
13:26 | FDA approves Gilead's Vemlidy sNDA for paediatric HBV patients | 4 | Pharmaceutical Business Review | ||
13:24 | Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update | 74 | GlobeNewswire (Europe) | AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and... ► Artikel lesen |
Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
---|---|---|---|---|---|---|---|
BAYER | 6 | 48 | +0,04 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
22.03.2024... ► Artikel lesen | ||
PFIZER | 5 | 19 | 0,00 % | Astellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China | BEIJING (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced that China's National Medical Products Administration or NMPA has accepted the supplemental Biologics License Application or sBLA for... ► Artikel lesen | ||
GILEAD SCIENCES | 5 | 15 | +0,09 % | Kurs von Gilead Sciences steigt etwas (68,1479 €) | Am US-amerikanischen Aktienmarkt liegt der Anteilsschein von Gilead Sciences aktuell im Plus. Der jüngste Kurs betrug 73,55 US-Dollar. Am Aktienmarkt liegt die Gilead Sciences-Aktie gegenwärtig im Plus.... ► Artikel lesen | ||
BRISTOL-MYERS SQUIBB | 5 | 9 | 0,00 % | Bristol Myers Squibb Company: Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes | Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United KingdomOriginally published on Bristol Myers Squibb NewsroomPRINCETON, NJ / ACCESSWIRE / March 29, 2024... ► Artikel lesen | ||
ACHIEVE LIFE SCIENCES | 5 | 7 | 0,00 % | Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update | SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and... ► Artikel lesen | ||
GALECTIN THERAPEUTICS | 5 | 6 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update | NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | ||
KALA BIO | 5 | 6 | -0,27 % | KALA BIO, Inc.: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources... ► Artikel lesen | ||
TIANJIN PHARMACEUTICAL DA REN TANG | 5 | 5 | 0,00 % | TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED: ANNUAL GENERAL MEETING::VOLUNTARY | |||
SCYNEXIS | 5 | 5 | -2,01 % | SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update | SCY-247's IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study... ► Artikel lesen | ||
TILRAY BRANDS | 4 | 31 | +0,18 % | Hausse! Canopy Growth, Aurora, Tilray und Co feiern deutsche Cannabis-Freigabe | Die am Freitag durch den Bundesrat erfolgte Teil-Legalisierung von Cannabis in Deutschland sorgt für haussierende Kurse der kanadischen Cannabis-Firmen. Vereinzelt gibt es Kursgewinne von über 40 Prozent.... ► Artikel lesen |
Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
---|---|---|---|---|---|---|---|---|---|
BAYER AG | 28,430 | 32,88 | +16 % | 6 | 33 | - | |||
MERCK KGAA | 163,60 | 188,20 | +15 % | 23 | - | - | |||
SANOFI SA | 89,79 | 101,50 | +13 % | 12 | 9 | 4 | |||
NOVARTIS AG | 89,75 | 99,33 | +11 % | 13 | 7 | 2 | |||
ELI LILLY AND COMPANY | 722,00 | 791,72 | +10 % | 1 | - | - | |||
PFIZER INC | 25,750 | 27,36 | +6 % | 2 | 8 | - | |||
ROCHE HOLDING AG GS | 235,70 | 249,98 | +6 % | 1 | 14 | 12 | |||
GSK PLC | 20,010 | 21,17 | +6 % | 18 | 3 | 8 | |||
ASTRAZENECA PLC | 125,95 | 132,33 | +5 % | 12 | 8 | 11 | |||
NOVO NORDISK A/S | 119,48 | 119,02 | 0 % | 25 | 12 | 3 | |||
DOCMORRIS AG | 92,98 | 88,90 | -4 % | 15 | 1 | 3 | |||
SCHOTT PHARMA AG & CO KGAA | 39,600 | 36,82 | -7 % | 2 | 9 | - |